Literature DB >> 3208811

Circulating drug levels in patients presenting cardiotoxicity to 5-FU.

A Thyss, G Milano, M Schneider, F Demard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3208811     DOI： 10.1016/0277-5379(88)90062-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  6 in total

Review 1.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

2.  Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.

Authors:  G Milano; M C Etienne; V Pierrefite; M Barberi-Heyob; R Deporte-Fety; N Renée
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 3.  5-fluorouracil and cardiotoxicity: a review.

Authors:  Jaskanwal D Sara; Jasvinder Kaur; Ryan Khodadadi; Muneeb Rehman; Ronstan Lobo; Sakti Chakrabarti; Joerg Herrmann; Amir Lerman; Axel Grothey
Journal:  Ther Adv Med Oncol       Date:  2018-06-18       Impact factor: 8.168

4.  What the Cardiologist Needs to Consider in the Management of Oncologic Patients with STEMI-Like Syndrome: A Case Report and Literature Review.

Authors:  Aneta Aleksova; Giulia Gagno; Alessandro Pierri; Carla Todaro; Alessandra Lucia Fluca; Valentina Orlando; Alessandra Guglielmi; Antonio Paolo Beltrami; Gianfranco Sinagra
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-12

5.  5-FU-induced cardiac toxicity--an underestimated problem in radiooncology?

Authors:  Felix Steger; Matthias G Hautmann; Oliver Kölbl
Journal:  Radiat Oncol       Date:  2012-12-15       Impact factor: 3.481

Review 6.  Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.

Authors:  Taro Shiga; Makoto Hiraide
Journal:  Curr Treat Options Oncol       Date:  2020-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.